The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study

The safety of SGLT-2 inhibitors in diabetic patients submitted to elective percutaneous coronary intervention regarding kidney function: SAFE-PCI pilot study

Abstract Background Percutaneous coronary intervention (PCI) is one of the most performed well-succeeded therapeutic procedures worldwide, reducing symptoms and improving quality of life. Neutrophil Gelatinase-associated Lipocalin (NGAL) is a biomarker of acute kidney injury (AKI) produced early aft...

Full description

Bibliographic Details
Main Authors: Mateus Paiva Marques Feitosa, Eduardo Gomes Lima, Alexandre Antônio Cunha Abizaid, Roxana Mehran, Neuza Helena Moreira Lopes, Thiago de Assis Fischer Ramos, Alexandre Hideo-Kajita, Roberto Kalil Filho, Carlos Vicente Serrano Junior
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Diabetology & Metabolic Syndrome
Subjects:
SGLT2 inhibitors
Coronary artery disease
Percutaneous coronary intervention
Acute kidney injury
Contrast-induced nephropathy
Online Access:https://doi.org/10.1186/s13098-023-01107-9

Internet

https://doi.org/10.1186/s13098-023-01107-9

Similar Items